For a 2.5mg dose, draw 50 units
Current clinical studies use a weekly schedule, with dose increases over time to support tolerability
At present, there is a balance payers must achieve across a variety of influencing factors on whether to cover GLP-1s (see Figure 1)
As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]
Each small tick mark = 1 unit (0.01 mL)
The theoretical advantage is smoother blood levels with less peak-to-trough variation, which may reduce the intensity of side effects, particularly nausea and appetite fluctuation